Casali Paolo, Pal Zsuzsanna, Xu Zhenming, Zan Hong
Center for Immunology, School of Medicine and School of Biological Sciences, University of California, Irvine, CA 92697-4120, USA.
Trends Immunol. 2006 Jul;27(7):313-21. doi: 10.1016/j.it.2006.05.001. Epub 2006 Jun 5.
Somatic hypermutation (SHM) underlies the generation of a diverse repertoire of high-affinity antibodies. It is effected by a two-step process: (i) DNA lesions initiated by activation-induced cytidine deaminase (AID), and (ii) lesion repair by the combined intervention of DNA replication and repair factors that include mismatch repair (MMR) proteins and translesion DNA synthesis (TLS) polymerases. AID and TLS polymerases that are crucial to SHM, namely polymerase (pol) theta, pol zeta and pol eta, are induced in B cells by the stimuli that are required to trigger this process: B-cell receptor crosslinking and CD40 engagement by CD154. These polymerases, together with MMR proteins and other DNA replication and repair factors, could assemble to form a multimolecular complex ("mutasome") at the site of DNA lesions. Molecular interactions in the mutasome would result in a "polymerase switch", that is, the substitution of the high-fidelity replicative pol delta and pol epsilon with the TLS pol theta, pol eta, Rev1, pol zeta and, perhaps, pol iota, which are error-prone and crucially insert mismatches or mutations while repairing DNA lesions. Here, we place these concepts in the context of the existing in vivo and in vitro findings, and discuss an integrated mechanistic model of SHM.
体细胞高频突变(SHM)是产生多种高亲和力抗体的基础。它通过两步过程实现:(i)由活化诱导的胞苷脱氨酶(AID)引发DNA损伤,以及(ii)通过包括错配修复(MMR)蛋白和跨损伤DNA合成(TLS)聚合酶在内的DNA复制和修复因子的联合干预进行损伤修复。对SHM至关重要的AID和TLS聚合酶,即聚合酶(pol)θ、pol ζ和pol η,在B细胞中由触发该过程所需的刺激诱导产生:B细胞受体交联和CD154介导的CD40结合。这些聚合酶与MMR蛋白以及其他DNA复制和修复因子一起,可在DNA损伤位点组装形成多分子复合物(“突变体”)。突变体中的分子相互作用将导致“聚合酶转换”,即高保真复制性pol δ和pol ε被TLS聚合酶pol θ、pol η、Rev1、pol ζ以及可能的pol ι替代,这些聚合酶容易出错,在修复DNA损伤时至关重要地插入错配或突变。在此,我们将这些概念置于现有的体内和体外研究结果背景下,并讨论SHM的综合机制模型。